Dmitrii Logash

About Dmitrii Logash

Clinical Research Professional driving breakthroughs in personalized medicine. Current: Harvard Medical School. Past: Bayer, Pfizer.Turning groundbreaking science into approved therapies at Bayer and Pfizer. Led the launch of FDA-approved tissue-agnostic cancer treatment, streamlined clinical operations, and managed strategic CNS portfolio development.Notable projects- First-in-class cancer therapy launch ($100M+ revenue)- Risk-based monitoring implementation ($400K annual optimization)- 30+ IRB submissions with 98% first-time approval- Cross-functional leadership in clinical operationsNow at Harvard Medical School\'s Clinical Research program while volunteering at Scripps Memorial Hospital, combining academic knowledge with practical healthcare experience.Looking to connect with professionals passionate about advancing clinical research and drug development.#ClinicalResearch #ClinicalTrials #DrugDevelopment #MedicalScience

Experience

1. Mobile Unit Clinical Research Coordinator

   Global Alzheimer's Platform Foundation

   Jun 2025 — Present · San Diego, CA, US

   Lead field execution across 3 Alzheimer’s initiatives, including 2 clinical research programs and the rollout of FDA-authorized blood-based biomarkers, partnering with 6+ clinical sites, healthcare professionals, and community stakeholders to expand referrals and patient access.Built and managed 40+ strategic partnerships across senior centers, faith-based organizations, nonprofits, caregiver groups, and other community-based organizations, strengthening trust and creating sustainable recruitment channels.Planned and delivered 45+ outreach and screening events within 3 quarters, contributing to a recruitment pipeline in which more than 60% of participants come from underrepresented communities.Conduct HCP outreach and multi-stakeholder engagement to support site recruitment goals, increase awareness of Alzheimer’s clinical research opportunities, and strengthen referral pathways across both community and clinical settings.Supported the field rollout of one of the first FDA-authorized blood-based biomarkers for Alzheimer’s disease by engaging KOLs, site leaders, and community partners to increase education, visibility, and adoption readiness.

Education

• Harvard Medical School Professional, Corporate, and Continuing Education

  Certificate Postgraduation Program, Foundations of Clinical Research

• Volgograd State Medical University

  Master's degree, Pharmaceutical Sciences

  2010 — 2017